Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Terminal complement inhibition is the standard of care for atypical hemolytic uremic syndrome (aHUS). The optimal duration of complement inhibition is unknown, although indefinite therapy is common. Here, we present the outcomes of a physician-directed eculizumab discontinuation and monitoring proto...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Chaturvedi, Shruti, Dhaliwal, Noor, Hussain, Sarah, Dane, Kathryn, Upreti, Harshvardhan, Braunstein, Evan M., Yuan, Xuan, Sperati, C. John, Moliterno, Alison R., Brodsky, Robert A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Thrombosis and Hemostasis
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948299/
https://ncbi.nlm.nih.gov/pubmed/33683339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003175
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi